Prospective, multicenter, phase II study on reducing the dosage of idarubicin and FLAG for patients younger than 65 years with resistant acute myeloid leukemia: a comparison with a higher dosage trial.

@article{Kim2014ProspectiveMP,
  title={Prospective, multicenter, phase II study on reducing the dosage of idarubicin and FLAG for patients younger than 65 years with resistant acute myeloid leukemia: a comparison with a higher dosage trial.},
  author={Hawk Kim and Jae-Hong Lee and Young-don Joo and Sung Hwa Bae and Jung-Hee Lee and Dae-Young Kim and W S Lee and H L Ryoo and Jae-Cheol Jo and J Park and K A Lee},
  journal={Acta haematologica},
  year={2014},
  volume={132 1},
  pages={87-96}
}
We previously assessed continuous infusion (CI) of fludarabine and cytarabine plus idarubicin (CI-FLAG1) for patients under 65 years of age with resistant acute myeloid leukemia. Induction chemotherapy consisted of idarubicin (IDA) plus fludarabine and cytarabine (ARAC) as a 24-hour CI. In response to induction, 31.6% of patients achieved complete remission (CR) and in 68.4% the treatment failed. We concluded that CI-FLAG1 carried a high risk of toxicity and reduced CI-FLAG doses were… CONTINUE READING